MDM2 and cancer: Several small-molecular compounds and peptides mimicking the MDM2 binding site of p53 have been reported to inhibit the MDM2:p53 interaction, antagonizing MDM2 and activating the p53 pathway in cancer cells [14], [17]–[19].